REPORT ID 6618

EMEA (Europe, Middle East and Africa) Neurotherapeutic Drugs Market Report 2017

Publish Date
26-Dec-17
Pages
102
Format
Electronic (PDF)

In this report, the EMEA Neurotherapeutic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Neurotherapeutic Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Neurotherapeutic Drugs market competition by top manufacturers/players, with Neurotherapeutic Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Abbott
    BD
    Novartis AG
    Johnson & Johnson
    Pfizer
    Sanofi-Aventis
    Biogen
    GlaxoSmithKline
    AstraZeneca
    Merck

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Peripheral Nervous System Disorders (PNS) Disorder
    Autonomous Nervous System (ANS) Disorder
    Central Nervous System (CNS) Disorders
    Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hosptical
    Drug Stores
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Neurotherapeutic Drugs Market Report 2017
1 Neurotherapeutic Drugs Overview
    1.1 Product Overview and Scope of Neurotherapeutic Drugs
    1.2 Classification of Neurotherapeutic Drugs
        1.2.1 EMEA Neurotherapeutic Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Neurotherapeutic Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Peripheral Nervous System Disorders (PNS) Disorder
        1.2.4 Autonomous Nervous System (ANS) Disorder
        1.2.5 Central Nervous System (CNS) Disorders
        1.2.6 Other
    1.3 EMEA Neurotherapeutic Drugs Market by Application/End Users
        1.3.1 EMEA Neurotherapeutic Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hosptical
        1.3.3 Drug Stores
        1.3.4 Other
    1.4 EMEA Neurotherapeutic Drugs Market by Region
        1.4.1 EMEA Neurotherapeutic Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Neurotherapeutic Drugs (2012-2022)
        1.5.1 EMEA Neurotherapeutic Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Neurotherapeutic Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Neurotherapeutic Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Neurotherapeutic Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Neurotherapeutic Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Neurotherapeutic Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Neurotherapeutic Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Neurotherapeutic Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Neurotherapeutic Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Neurotherapeutic Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Neurotherapeutic Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Neurotherapeutic Drugs (Volume) by Application
    2.4 EMEA Neurotherapeutic Drugs (Volume and Value) by Region
        2.4.1 EMEA Neurotherapeutic Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Neurotherapeutic Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Neurotherapeutic Drugs Sales Price by Region (2012-2017)

3 Europe Neurotherapeutic Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Neurotherapeutic Drugs Sales and Value (2012-2017)
        3.1.1 Europe Neurotherapeutic Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Neurotherapeutic Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Neurotherapeutic Drugs Sales and Market Share by Type
    3.3 Europe Neurotherapeutic Drugs Sales and Market Share by Application
    3.4 Europe Neurotherapeutic Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Neurotherapeutic Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Neurotherapeutic Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)

4 Middle East Neurotherapeutic Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Neurotherapeutic Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Neurotherapeutic Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Neurotherapeutic Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Neurotherapeutic Drugs Sales and Market Share by Type
    4.3 Middle East Neurotherapeutic Drugs Sales and Market Share by Application
    4.4 Middle East Neurotherapeutic Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Neurotherapeutic Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Neurotherapeutic Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)

5 Africa Neurotherapeutic Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Neurotherapeutic Drugs Sales and Value (2012-2017)
        5.1.1 Africa Neurotherapeutic Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Neurotherapeutic Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Neurotherapeutic Drugs Sales and Market Share by Type
    5.3 Africa Neurotherapeutic Drugs Sales and Market Share by Application
    5.4 Africa Neurotherapeutic Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Neurotherapeutic Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Neurotherapeutic Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Neurotherapeutic Drugs Sales and Growth Rate (2012-2017)

6 EMEA Neurotherapeutic Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Abbott
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Abbott Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 BD
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 BD Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Johnson & Johnson
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Johnson & Johnson Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Pfizer
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Pfizer Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Sanofi-Aventis
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Sanofi-Aventis Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Biogen
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Biogen Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 GlaxoSmithKline
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 GlaxoSmithKline Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 AstraZeneca
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 AstraZeneca Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Merck
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Neurotherapeutic Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Merck Neurotherapeutic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Neurotherapeutic Drugs Manufacturing Cost Analysis
    7.1 Neurotherapeutic Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Neurotherapeutic Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Neurotherapeutic Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Neurotherapeutic Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Neurotherapeutic Drugs Market Forecast (2017-2022)
    11.1 EMEA Neurotherapeutic Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Neurotherapeutic Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Neurotherapeutic Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Neurotherapeutic Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Neurotherapeutic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Neurotherapeutic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Neurotherapeutic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Neurotherapeutic Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Neurotherapeutic Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Neurotherapeutic Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer